A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
OPEN TO ACCRUAL
III
NCT06246916
mconstantinou@BrownHealth.org
